Equity Overview
Price & Market Data
Price: $42.23
Daily Change: -$0.85 / 2.01%
Daily Range: $41.44 - $43.18
Market Cap: $3,263,323,648
Daily Volume: 728,305
Performance Metrics
1 Week: 1.47%
1 Month: 3.00%
3 Months: 3.99%
6 Months: 12.19%
1 Year: 7.24%
YTD: -5.78%
Company Details
Employees: 327
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.